Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
chronic kidney disease
Biotech
R1 debuts with $77.5M to advance kidney disease treatment
R1 Therapeutics is debuting with $77.5 million aimed at advancing its first-in-class therapy for patients on dialysis with chronic kidney disease (CKD).
Will Maddox
Mar 17, 2026 7:00am
United Therapeutics' temporary liver shows promise in trial
Jan 27, 2026 9:00am
Boehringer spells out a $448M future for Rectify's ABC program
Dec 22, 2025 9:45am
Novo Nordisk vs. KBP: From $1.3B deal to legal battlefield
Oct 2, 2025 3:00am
ProKidney cell therapy wins half of trial, falls short on other
Jul 8, 2025 8:00am
Mineralys drug lowers blood pressure in yet another clinical win
Jun 17, 2025 9:25am
